IDEFIRIX

This brand name is authorized in Austria, Estonia, Finland, Croatia, Ireland, Israel, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug IDEFIRIX contains one active pharmaceutical ingredient (API):

1 Imlifidase UNII UVJ7NL8S2P - IMLIFIDASE

Imlifidase is a cysteine protease derived from the immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that cleaves the heavy chains of all human IgG subclasses but no other immunoglobulins. The cleavage of IgG leads to elimination of Fc-dependent effector functions, including CDC and antibody-dependent cell-mediated cytotoxicity (ADCC). By cleaving all IgG, imlifidase reduces the level of DSA, thus enabling transplantation. Read about Imlifidase

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IDEFIRIX Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AA41		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1826243, 1826254
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 084630, 595693
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 391969, 391970
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9440, 9441
Country: IT	Agenzia del Farmaco	Identifier(s): 048988012, 048988024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091050, 1091051
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100441882